Company Focus
Moderna
Latest Moderna News
Biotechnology
US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 November 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to Moderna
Biotechnology
The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Descartes-08. 22 May 2024
Biotechnology
US immunology specialist AltruBio announced an oversubscribed Series B financing of up to $225 million. 22 May 2024
Biotechnology
The annual meeting of the American Society of Clinical Oncology (ASCO) is set to commence on 2 June in Chicago, with the highly anticipated plenary session taking place on the Sunday. 22 May 2024
Biotechnology
A partial clinical hold affecting progress at Larimar Therapeutics has been lifted by the US Food and Drug Administration. 22 May 2024
Biotechnology
A new subcutaneous version of the checkpoint blocker Opdivo (nivolumab) could be approved earlier than expected, after the US regulator brought forward the date for a decision. 22 May 2024
Biotechnology
Medigene has extended a deal with fellow German company BioNTech to advance T cell receptor (TCR) immunotherapies. 21 May 2024
Biotechnology
Massachusetts-USA-based biotech-Progentos Therapeutics has announced its launch and the closing of a $65 million Series A round of financing. 21 May 2024
Pharmaceutical
While AstraZeneca’s chief executive Pascal Soriot has been proven right about many of his prior boasts on the company’s future success during his 12-year reign, his latest claim could be questioned even by his strongest supporters. 21 May 2024
Biotechnology
The European Commission (EC) has decided not to adopt the European Medicines Agency’ human medicines committee CHMP's negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna (ataluren) and has returned the opinion to the CHMP for re-evaluation. 21 May 2024
Biotechnology
Shares of Massachusetts, USA-based muscle specialist Dyne Therapeutics closed up almost 28% at $35.38 yesterday, after it released positive clinical data from its ongoing Phase I/II ACHIEVE trial of DYNE-101. 21 May 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
BeiGene has announced plans to rebrand as BeOne Medicines, a move the cancer specialist says reflects its commitment to fighting cancer through collaboration. 15 November 2024
5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze